Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 58 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$14.99|
|52-week range||$6.17 - $60.00|
|50-day moving average||$16.70|
|200-day moving average||$21.87|
|Wall St. target price||$59.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-06)||4.90%|
|1 month (2021-09-16)||-13.65%|
|3 months (2021-07-16)||-20.86%|
|6 months (2021-04-16)||-40.80%|
|1 year (2020-10-16)||114.76%|
|2 years (2019-10-16)||2,261.00%|
|3 years (2018-10-16)||241.46%|
|5 years (2016-10-14)||524.58%|
|Revenue TTM||$9.4 million|
|Gross profit TTM||$-13,543,000|
|Return on assets TTM||-35.67%|
|Return on equity TTM||-265%|
|Market capitalisation||$71 million|
TTM: trailing 12 months
There are currently 63,957 Aptevo Therapeutics shares held short by investors – that's known as Aptevo Therapeutics's "short interest". This figure is 13.9% down from 74,286 last month.
There are a few different ways that this level of interest in shorting Aptevo Therapeutics shares can be evaluated.
Aptevo Therapeutics's "short interest ratio" (SIR) is the quantity of Aptevo Therapeutics shares currently shorted divided by the average quantity of Aptevo Therapeutics shares traded daily (recently around 61497.115384615). Aptevo Therapeutics's SIR currently stands at 1.04. In other words for every 100,000 Aptevo Therapeutics shares traded daily on the market, roughly 1040 shares are currently held short.
However Aptevo Therapeutics's short interest can also be evaluated against the total number of Aptevo Therapeutics shares, or, against the total number of tradable Aptevo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptevo Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Aptevo Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0245% of the tradable shares (for every 100,000 tradable Aptevo Therapeutics shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptevo Therapeutics.
Find out more about how you can short Aptevo Therapeutics stock.
We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.
Aptevo Therapeutics's shares were split on a 1:14 basis on 26 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.
Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $6.17 up to $60. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 6.9392. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG. APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.